Soligenix (SNGX) Accumulated Expenses (2010 - 2026)
Soligenix's (SNGX) quarterly Accumulated Expenses came in at $43001.0 in Q1 2026, down 98.62% YoY from $3.1 million in Q1 2025, and down 91.19% on a QoQ basis from $488125.0 in Q4 2025.
Soligenix (SNGX) Accumulated Expenses (2010 - 2026) Analysis & Trends
Soligenix (SNGX) has 17 years of Accumulated Expenses data on file, last reported at $43001.0 in Q1 2026.
- Quarterly Accumulated Expenses fell 98.62% year-over-year to $43001.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43001.0 (down 98.62% YoY) and the FY2025 annual result came in at $488125.0, up 45.08% from the prior year.
- Accumulated Expenses declined to $43001.0 in Q1 2026, from $488125.0 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $3.1 million in Q1 2025 to a low of $43001.0 in Q1 2026.
- A 5-year average of $1.2 million and a median of $488125.0 in 2025 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2025 — Accumulated Expenses jumped 6110.84% — and 2026, when it plunged 98.62%.
- Tracing SNGX's Accumulated Expenses over 5 years: stood at $2.3 million in 2022, then slumped by 89.12% to $251115.0 in 2023, then jumped by 33.98% to $336442.0 in 2024, then surged by 45.08% to $488125.0 in 2025, then tumbled by 91.19% to $43001.0 in 2026.
- The last three Accumulated Expenses figures came in at $43001.0 (Q1 2026), $488125.0 (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Soligenix | 6.45 Mn | 6.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.06 Mn |
| Mar 31, 2026 | 43,001.00 |
| Dec 31, 2025 | 488,125.00 |
| Sep 30, 2025 | 2.03 Mn |
| Jun 30, 2025 | 2.78 Mn |
| Mar 31, 2025 | 3.12 Mn |
| Dec 31, 2024 | 336,442.00 |
| Sep 30, 2024 | 1.36 Mn |
| Jun 30, 2024 | 80,244.00 |
| Mar 31, 2024 | 50,216.00 |
| Dec 31, 2023 | 251,115.00 |
| Sep 30, 2023 | 55,543.00 |
| Jun 30, 2023 | 73,861.00 |
| Mar 31, 2023 | 2.45 Mn |
| Dec 31, 2022 | 2.31 Mn |
| Sep 30, 2022 | 59,790.00 |
| Jun 30, 2022 | 2.44 Mn |
| Mar 31, 2022 | 2.59 Mn |
| Dec 31, 2021 | 2.96 Mn |
| Sep 30, 2021 | 58,729.00 |